Merck & Company Inc(0QAH)
USD --+0.00%
Reward43Moderate
Risk17Low
75%Data
Thin 5% profit margin · 2.2% dividend yield
0QAH
+0.0 · +0.00%
USD · LSE
Merck & Company Inc |
Defensive Anchor
Market Cap:384.04Bn
ⓘ
Reward Rating
43
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
17
Low
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0QAH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for 0QAH, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Merck & Company Inc?

operates as a healthcare company worldwide.

0QAH · Verdict

Moderate reward · low risk

0QAH stands out on volatility and cash flow, but watch the valuation signal.

Based on 88% data coverage

0QAH · Verdict

What’s working & what to watch

Strengths 3

  • Volatility95/100

    Top decile vs peers

  • Cash flow89/100

    19% free-cash-flow margin

  • Profitability71/100

    28% net margin · 7% ROE

Watchouts 2

  • Valuation13/100

    P/E 55.2× · PEG 10.43

  • Growth35/100

    Rev +3.1% CAGR · earnings +7.9%

Model-based scoring. For information only — not financial advice.

What is Merck & Company Inc?

operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company is listed on the LSE in UK, with a market capitalisation of 384.04B, and a P/E ratio of 0.2x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (43)

The scoring profile indicates limited reward potential at this time, with profitability and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
IndustryN/A
Market Cap384.04B
P/E Ratio0.2209
Dividend Yield2.19%
Beta0.211
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.